Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Røe, Kathrine ^a,b,c   Mikalsen, Lars T G ^b   van der Kogel, Albert J ^d,e   Bussink, Johan ^d   Lyng, Heidi ^a   Ree, Anne H ^b,c   Marignol, Laure ^f   Olsen, Dag R ^g  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f ST JAMES S HOSPITAL   (Ireland)

^g UNIVERSITY OF BERGEN   (Norway)

Author keywords

Androgen deprivation therapy; Dynamic contrast enhanced MRI; Immunohistochemistry; Prostate cancer; Radiotherapy

Indexed keywords

HOE 33342; PIMONIDAZOLE;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENSITY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TISSUE SECTION; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANDROGENS; ANIMALS; BLOOD VESSELS; CARCINOMA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; ORCHIECTOMY; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861330888     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-75     Document Type: Article

References (40)

1. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004, 61:332-353. 10.1002/pros.20115, 15389811.
2. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459. 10.1016/S1470-2045(11)70063-8, 21440505.
3. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD, . Scandinavian Prostate Cancer Group Study 7, Swedish Association for Urological Oncology 3 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308. 10.1016/S0140-6736(08)61815-2, 19091394, Scandinavian Prostate Cancer Group Study 7, Swedish Association for Urological Oncology 3.
4. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11:393-410. 10.1038/nrc3064, 21606941.
5. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 2008, 149:2959-2969. 10.1210/en.2007-1078, 2408806, 18292195.
6. Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 2011, 300:E263-E275. 10.1152/ajpendo.00210.2010, 3280699, 20699437.
7. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007, 8:63-74. 10.1016/S1470-2045(06)71012-9, 17196512.
8. Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR, Smith GJ. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS One 2012, 7:29623.
9. Dyke JP, Zakian KZ, Spees WM, Matei C, Chen Y, Mao X, Shungu DC, Koutcher JA. Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1 H spectroscopic imaging. Clin Cancer Res 2003, 9:4529-4536.
10. Røe K, Seierstad T, Kristian A, Mikalsen LT, Maelandsmo GM, van der Kogel AJ, Ree AH, Olsen DR. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions. Neoplasia 2010, 12:818-825. 2950331, 20927320.
11. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232. 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S, 10508281.
12. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J. Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 1994, 31:567-571. 10.1002/mrm.1910310516, 8015413.
13. Hendriksen EM, Span PN, Schuuring J, Peters JP, Sweep FC, van der Kogel AJ, Bussink J. Angiogenesis, hypoxia and VEGF expression during tumor growth in a human xenograft tumour model. Microvasc Res 2009, 77:96-103. 10.1016/j.mvr.2008.11.002, 19118564.
14. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, Resnick MI, Seftel A, Pretlow TG. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994, 54:6049-6052.
15. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
16. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction?. Cancer Treat Rev 2008, 34:313-327. 10.1016/j.ctrv.2008.01.006, 18334284.
17. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2009, 105:8-13.
18. Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, Harris AL, Hammond EM. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 2010, 70:925-935. 10.1158/0008-5472.CAN-09-2715, 2923514, 20103649.
19. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007, 26:333-339. 10.1007/s10555-007-9063-1, 17458506.
20. Bristow RG, Hill RP. Hypoxia, DNA repair and genetic instability. Nature Rev Cancer 2008, 8:180-192.
21. Borre M, Offersen BV, Nerstrøm B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998, 78:940-944. 10.1038/bjc.1998.605, 2063118, 9764587.
22. Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, de Torres I. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006, 21:857-865.
23. Bostwick DG, Iczkowski KA. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 1998, 16:118-123.
24. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy?. Int J Radiat Oncol Biol Phys 2000, 48:545-553. 10.1016/S0360-3016(00)00677-5, 10974475.
25. Folkvord S, Flatmark K, Dueland S, de Wijn R, Groholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH. Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys 2010, 78:555-562. 10.1016/j.ijrobp.2010.04.036, 20675069.
26. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005, 23:1782-1790. 10.1200/JCO.2005.12.017, 15755986.
27. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9:10-17.
28. Lekas E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997, 25:309-314. 10.1007/BF01294656, 9373910.
29. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998, 36:201-206. 10.1002/(SICI)1097-0045(19980801)36:3<201::AID-PROS9>3.0.CO;2-J, 9687993.
30. de la Taille A, Chen MW, Shabsigh A, Bagiella E, Kiss A, Buttyan R. Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland. Prostate 1999, 40:89-96. 10.1002/(SICI)1097-0045(19990701)40:2<89::AID-PROS4>3.0.CO;2-E, 10386469.
31. Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen MW, Burchardt T, Olsson CA, Buttyan R. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J Urol 1999, 162:1527-1531. 10.1016/S0022-5347(05)68352-8, 10492249.
32. Alonzi R, Padhani AR, Taylor NJ, Collins DJ, D'Arcy JA, Stirling JJ, Saunders MI, Hoskin PJ. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys 2011, 80:721-727. 10.1016/j.ijrobp.2010.02.060, 20630668.
33. Lorke DE, Wenzel S, Siebert K, Zywietz F. Microvascular and tumor cell alterations during continuous hyperfractionated irradiation: an electron microscopic investigation on the rat R1H rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 1999, 44:895-904. 10.1016/S0360-3016(99)00073-5, 10386648.
34. Bussink J, Kaanders JH, Rijken PF, Raleigh JA, van der Kogel AJ. Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res 2000, 153:398-404. 10.1667/0033-7587(2000)153[0398:CIBPAH]2.0.CO;2, 10760999.
35. Horsman MR, Nielsen T, Østergaard L, Overgaard L. Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response. Acta Oncol 2006, 45:876-880. 10.1080/02841860600900068, 16982553.
36. Egeland TAM, Gulliksrud K, Gaustad JV, Mathiesen B, Rofstad EK. Dynamic contrast-enhanced-MRI of tumor hypoxia. Magn Reson Med 2012, 67:519-530. 10.1002/mrm.23014, 21661044.
37. Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ. Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia 2007, 9:382-391. 10.1593/neo.07145, 1877977, 17534443.
38. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJS. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21:2831-2842. 10.1200/JCO.2003.05.187, 12807936.
39. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1554. 10.1093/jnci/djm135, 17895480.
40. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004, 14:198-206. 10.1016/j.semradonc.2004.04.008, 15254862.